Fundz

Passage Bio, Inc. Reports Interim Data from upliFT-D Study for PBFT02 Treatment of Frontotemporal Dementia.

Jan 10, 2025
United StatesBiotechnologyHealthcareHealth CareGeneticsTherapeutics

Product Description

Passage Bio, Inc. announced updated interim data from its ongoing upliFT-D clinical trial for PBFT02 aimed at treating frontotemporal dementia. They also completed a manufacturing process for PBFT02 and extended their cash runway to support future milestones.

Company Information

Company

Passage Bio

Location

United States

About

Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.

Fundz sees it the moment Passage Bio ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Will hidden

hidden
Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Passage Bio's next move

Learn about Strategic plan

Product Launch Insights

What this usually means
Market expansion signals
New product launches often coincide with market expansion initiatives

Passage Bio shipped something new. Fundz reads product launches, trademark filings and hiring together.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.